Dividend and Share Capital - The company plans to distribute a cash dividend of 23.00 CNY per 10 shares (including tax), totaling approximately 517.74 million CNY based on 225,104,736 shares after excluding repurchased shares[8]. - The company reported a total share capital of 227,204,736 shares as of the report date, with 2,100,000 shares held in the repurchase account not participating in the dividend distribution[8]. - The company's net profit attributable to ordinary shareholders for 2020 was RMB 2,549,453,200.21, with a dividend payout ratio of 20.31%[179]. - The cash dividend policy aims to provide continuous and stable cash dividends while ensuring the company's operational growth[176]. - The company completed its share repurchase ahead of schedule due to business needs and operational conditions[174]. - The company repurchased a total of 2,100,000 shares, accounting for 0.92% of the total share capital, with a total transaction amount of RMB 133,344,319.82[174]. Financial Performance - The company's operating revenue for 2020 reached ¥10,398,545,638.73, a significant increase of 456.75% compared to ¥1,867,727,915.16 in 2019[29]. - Net profit attributable to shareholders was ¥2,549,453,200.21, up 1,524.99% from ¥156,890,061.60 in the previous year[29]. - The net cash flow from operating activities increased to ¥3,120,839,894.43, representing a growth of 1,478.07% compared to ¥197,762,736.75 in 2019[29]. - Basic earnings per share rose to ¥12.50, a 1,462.50% increase from ¥0.80 in 2019[29]. - The weighted average return on equity increased to 94.88%, up 81.6 percentage points from 13.28% in 2019[29]. - The company's net assets attributable to shareholders grew to ¥4,182,785,620.66, a 207.83% increase from ¥1,358,786,069.59 at the end of 2019[29]. - Total assets increased to ¥6,400,086,700.05, reflecting a growth of 139.77% compared to ¥2,669,238,311.75 in 2019[29]. Risk Management and Compliance - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[10]. - The company has not violated decision-making procedures for external guarantees[10]. - The company has maintained the accuracy and completeness of the annual report as confirmed by its board of directors and management[5]. - The company has not reported any instances of more than half of the directors being unable to guarantee the authenticity of the annual report[10]. - The company emphasizes that forward-looking statements in the report do not constitute a substantive commitment to investors, highlighting potential investment risks[9]. - The company has detailed potential risks in the "Discussion and Analysis of Operating Conditions" section of the report[12]. Market and Sales Strategy - The increase in revenue was primarily driven by a surge in sales of pandemic-related protective products and the consolidation of Rocialle Healthcare Limited's financials following the acquisition of a 55% stake[30]. - The company has established a marketing network covering over 5,300 hospitals in China, including more than 800 top-tier hospitals[43]. - The company has a 95% coverage rate in the top 100 chain pharmacies across the country, totaling over 70,000 pharmacy stores[43]. - The company operates over 10 online stores on platforms like Tmall, JD, and Pinduoduo, with a total fan base exceeding 5 million[43]. - The company ranks among the top three in China's medical dressing exports for several consecutive years[43]. Research and Development - The company has invested a total of ¥40,052.70 million from its IPO proceeds into fundraising projects, ensuring production capacity for its wound care and surgical infection control products[89]. - Research and development expenses surged by 409.70% to ¥259,712,735.22, up from ¥50,953,817.91 in the previous year[91]. - The company is focusing on enhancing its R&D capabilities, with several projects in clinical trials and product registration stages, including a dermal substitute and a skin cell enrichment device[135]. - The company has recognized the need for continuous improvement in its supply chain and quality management systems to mitigate product quality risks[167]. Acquisitions and Investments - The company acquired 70% equity of Suzhou Medis for a total transaction amount of CNY 104.16 million, with payments of CNY 62.50 million made in early 2019 and CNY 20.83 million during the reporting period[141]. - The company invested CNY 30 million to subscribe for additional capital of CNY 3.15 million in Stanger, acquiring a total of 60% equity after a cash purchase of CNY 45 million[141]. - The company acquired 65% equity of Hangzhou Xindong for CNY 1.95 million, completing the registration procedures during the reporting period[141]. - The company approved an investment of approximately CNY 360 million for the relocation and expansion of production lines for wound care products and surgical control products, with partial completion by the end of the reporting period[142]. Operational Efficiency - The company implemented lean manufacturing and smart factory initiatives to enhance operational efficiency and supply chain responsiveness[81]. - The company aims to strengthen its strategic partnerships with international and regional clients to further develop new product lines and increase market share[158]. - The company plans to gradually reduce shareholdings after the lock-up period, with annual reductions not exceeding 5% of the total share capital at the end of the previous year[191]. Future Outlook - The company aims to become a leading healthcare enterprise with a market value of over 100 billion RMB by focusing on "medical + health" sectors and enhancing digital operations and continuous R&D[154]. - The company plans to invest approximately RMB 12,000 million in a medical protective gear R&D and industrialization project, which is yet to commence[174]. - The company will enhance its digital marketing capabilities and improve operational efficiency through the integration of online and offline channels in the retail market[158]. - The company is actively seeking strategic acquisition opportunities in niche markets and key technologies globally[164].

I. Important Notice The company's management assures the truthfulness and completeness of this quarterly report, taking full legal responsibility - The company's board of directors, supervisory board, and all directors, supervisors, and senior management guarantee the truthfulness, accuracy, and completeness of this quarterly report, free from false records, misleading statements, or major omissions, and assume corresponding legal responsibilities[8](index=8&type=chunk) - This company's Q1 2021 report is unaudited[11](index=11&type=chunk) II. Company Profile This section provides an overview of the company's key financial performance and shareholder structure [2.1 Key Financial Data](index=3&type=section&id=2.1%20Key%20Financial%20Data) In Q1 2021, the company achieved explosive growth with revenue up 181.26% and net profit attributable to shareholders up 195.85%, driven by increased sales of epidemic prevention products and strong growth in conventional business Key Financial Data for Q1 2021 | Indicator | Current Period | Prior Year Same Period | Year-on-Year Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (Yuan) | 1,994,536,800.50 | 709,139,585.11 | 181.26% | | Net Profit Attributable to Shareholders (Yuan) | 254,172,328.25 | 85,912,862.61 | 195.85% | | Net Profit Attributable to Shareholders (Excluding Non-recurring Items) (Yuan) | 236,981,089.46 | 87,300,052.13 | 171.46% | | Net Cash Flow from Operating Activities (Yuan) | 229,569,623.19 | 197,190,457.14 | 16.42% | | Basic Earnings Per Share (Yuan/share) | 1.12 | 0.44 | 154.55% | | Weighted Average Return on Net Assets (%) | 5.96% | 6.13% | Decrease of 0.17 percentage points | - Revenue growth was primarily driven by a significant increase in sales of epidemic prevention products (masks, protective suits, isolation gowns) and growth in non-epidemic related businesses, with main business revenue reaching **1.991 billion Yuan**, a **181.59% year-on-year increase**[15](index=15&type=chunk) - Excluding epidemic prevention products, the company's main business revenue was **993 million Yuan**, a **119.49% year-on-year increase** on a comparable basis, demonstrating strong organic growth in core businesses[15](index=15&type=chunk) - Total non-recurring gains and losses for the reporting period amounted to **17.19 million Yuan**, primarily from government subsidies and gains/losses from entrusted investments or asset management[16](index=16&type=chunk)[19](index=19&type=chunk) [2.2 Total Number of Shareholders, Top Ten Shareholders, and Top Ten Circulating Shareholders (or Non-Restricted Shareholders) as of the End of the Reporting Period](index=5&type=section&id=2.2%20Total%20Number%20of%20Shareholders%2C%20Top%20Ten%20Shareholders%2C%20and%20Top%20Ten%20Circulating%20Shareholders%20%28or%20Non-Restricted%20Shareholders%29%20as%20of%20the%20End%20of%20the%20Reporting%20Period) As of the end of the reporting period, the company had 48,091 shareholders, with Zhejiang Zhende Holding Co Ltd as the controlling shareholder at 48.06%, and the actual controllers being Mr. Lu Jianguo and Ms. Shen Zhenfang - As of the end of the reporting period, the company had **48,091 shareholders**[19](index=19&type=chunk) Top Five Shareholders' Holdings | Shareholder Name | Number of Shares Held | Shareholding Percentage (%) | | :--- | :--- | :--- | | Zhejiang Zhende Holding Co Ltd | 109,191,600 | 48.06 | | Shen Zhenfang | 9,310,000 | 4.10 | | Lou Zhangdian | 2,101,600 | 0.92 | | Zhende Medical Products Co Ltd Repurchase Special Securities Account | 2,100,000 | 0.92 | | Lu Zhiying | 1,896,000 | 0.83 | - The shares held by controlling shareholder Zhejiang Zhende Holding Co Ltd and one of the company's actual controllers, Shen Zhenfang, are restricted shares; Lu Jianguo holds **83.50%** of Zhejiang Zhende, and he and Shen Zhenfang are a married couple, serving as the company's joint actual controllers[22](index=22&type=chunk) III. Significant Events This section details major financial changes, progress on significant matters, and commitments [3.1 Significant Changes in Major Accounting Statement Items and Financial Indicators of the Company and Their Reasons](index=6&type=section&id=3.1%20Significant%20Changes%20in%20Major%20Accounting%20Statement%20Items%20and%20Financial%20Indicators%20of%20the%20Company%20and%20Their%20Reasons) During the reporting period, several financial statement items showed significant changes due to business expansion and accounting standard changes, with revenue, costs, and expenses increasing substantially, and new right-of-use assets and lease liabilities recognized under new leasing standards, alongside a **246.98% increase in R&D expenses** Significant Changes in Consolidated Income Statement Items | Item | Current Period Amount (Yuan) | Prior Year Same Period (Yuan) | Change (%) | Primary Reason | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 1,994,536,800.50 | 709,139,585.11 | 181.26% | Sales of epidemic prevention products and growth in conventional business | | Operating Cost | 1,242,954,241.51 | 410,733,839.84 | 202.62% | Increased proportionally with revenue growth | | Selling Expenses | 178,043,461.88 | 79,674,592.83 | 123.46% | Increase in sales service fees and personnel salaries | | Administrative Expenses | 155,995,087.59 | 82,925,774.64 | 88.11% | Increase in management personnel and salaries, and project investments | | R&D Expenses | 50,728,197.29 | 14,619,882.05 | 246.98% | Increase in R&D investment | | Financial Expenses | 2,128,390.55 | 8,705,805.55 | -75.55% | Impact of convertible bond redemption in prior year | | Non-controlling Interests | 56,148,766.13 | 643,229.40 | 8,629.20% | Significant increase in net profit of UK subsidiary Rocialle Healthcare | Significant Changes in Consolidated Balance Sheet Items | Item | End of Current Reporting Period (Yuan) | End of Prior Year (Yuan) | Change (%) | Primary Reason | | :--- | :--- | :--- | :--- | :--- | | Right-of-Use Assets | 77,060,007.25 | 0 | - | Implementation of new leasing standards | | Intangible Assets | 332,248,036.72 | 225,622,351.56 | 47.26% | Prepaid land payments transferred in | | Lease Liabilities | 63,614,691.58 | 0 | - | Implementation of new leasing standards | | Long-term Borrowings | 0 | 95,117,562.50 | -100.00% | Repayment of long-term borrowings | Significant Changes in Consolidated Cash Flow Statement Items | Item | Current Period Amount (Yuan) | Prior Year Same Period (Yuan) | Change (%) | Primary Reason | | :--- | :--- | :--- | :--- | :--- | | Net Cash Flow from Investing Activities | 215,158,415.67 | -255,684,540.55 | - | Redemption of wealth management products increased cash inflow | | Net Cash Flow from Financing Activities | -231,357,023.08 | 106,802,902.84 | -316.62% | Repayment of long-term borrowings and share repurchases increased cash outflow | [3.2 Analysis and Explanation of Progress, Impact, and Solutions for Significant Matters](index=8&type=section&id=3.2%20Analysis%20and%20Explanation%20of%20Progress%2C%20Impact%2C%20and%20Solutions%20for%20Significant%20Matters) During the reporting period, the company completed its share repurchase plan, repurchasing **2.1 million shares** (0.92% of total capital), while Suzhou Medis fulfilled its two-year performance commitments, and the company invested in Baoma Medical, acquiring a **4.95% stake** to expand into minimally invasive surgical consumables - The company completed its share repurchase plan, cumulatively repurchasing **2,100,000 shares**, accounting for **0.92%** of the total share capital, with a total value of **133 million Yuan**, and the repurchased shares will be used for equity incentive plans[30](index=30&type=chunk) - Suzhou Medis Medical Sports Products Co Ltd, acquired by the company, has fulfilled its performance commitments for 2019 and 2020, and related goodwill has been tested and found not to be impaired[30](index=30&type=chunk) - The company invested **49.5 million Yuan** in Baoma Medical Technology (Wuxi) Co Ltd through capital increase and equity acquisition, holding a **4.95% stake** post-transaction, aiming to expand into the field of minimally invasive surgical consumables[30](index=30&type=chunk)[33](index=33&type=chunk) [3.3 Unfulfilled Commitments Beyond Due Date During the Reporting Period](index=9&type=section&id=3.3%20Unfulfilled%20Commitments%20Beyond%20Due%20Date%20During%20the%20Reporting%20Period) During the reporting period, the company had no unfulfilled commitments beyond their due date - The company had no unfulfilled commitments beyond their due date during this reporting period[34](index=34&type=chunk) [3.4 Warning and Explanation Regarding Potential Cumulative Net Profit Loss or Significant Change Compared to the Same Period Last Year from the Beginning of the Year to the End of the Next Reporting Period](index=9&type=section&id=3.4%20Warning%20and%20Explanation%20Regarding%20Potential%20Cumulative%20Net%20Profit%20Loss%20or%20Significant%20Change%20Compared%20to%20the%20Same%20Period%20Last%20Year%20from%20the%20Beginning%20of%20the%20Year%20to%20the%20End%20of%20the%20Next%20Reporting%20Period) The company has not issued any warnings regarding potential cumulative net profit loss or significant year-on-year changes from the beginning of the year to the end of the next reporting period - The company has not issued any forecast warnings regarding significant changes or losses in cumulative net profit from the beginning of the year to the end of the next reporting period[34](index=34&type=chunk) IV. Appendix This section includes the unaudited financial statements for the reporting period [4.1 Financial Statements](index=9&type=section&id=4.1%20Financial%20Statements) This section provides the company's unaudited consolidated and parent company financial statements for Q1 2021, including the balance sheet, income statement, and cash flow statement, comprehensively reflecting the financial position, operating results, and cash flows for the period [Consolidated Balance Sheet](index=9&type=section&id=Consolidated%20Balance%20Sheet) As of March 31, 2021, the company's total assets were **6.579 billion Yuan**, a **2.80% increase** from the end of the prior year, with net assets attributable to shareholders at **4.301 billion Yuan**, up **2.83%** Key Items from Consolidated Balance Sheet (March 31, 2021) | Item | Amount (Yuan) | | :--- | :--- | | **Assets** | | | Cash and Cash Equivalents | 1,852,822,693.31 | | Accounts Receivable | 659,817,933.00 | | Inventories | 1,066,089,686.26 | | **Total Assets** | **6,579,297,872.18** | | **Liabilities** | | | Short-term Borrowings | 350,356,736.11 | | Accounts Payable | 682,751,907.00 | | **Total Liabilities** | **1,937,100,394.35** | | **Shareholders' Equity** | | | Equity Attributable to Parent Company Owners | 4,301,318,433.74 | | **Total Shareholders' Equity** | **4,642,197,477.83** | [Parent Company Balance Sheet](index=12&type=section&id=Parent%20Company%20Balance%20Sheet) As of March 31, 2021, the parent company's total assets were **4.306 billion Yuan**, total liabilities were **1.361 billion Yuan**, and the asset-liability ratio was **31.61%** Key Items from Parent Company Balance Sheet (March 31, 2021) | Item | Amount (Yuan) | | :--- | :--- | | **Assets** | | | Cash and Cash Equivalents | 857,283,091.17 | | Prepayments | 851,291,004.33 | | **Total Assets** | **4,306,246,005.78** | | **Liabilities** | | | Short-term Borrowings | 250,255,902.78 | | Other Payables | 555,975,788.99 | | **Total Liabilities** | **1,361,343,181.42** | | **Shareholders' Equity** | | | **Total Owners' Equity** | **2,944,902,824.36** | [Consolidated Income Statement](index=14&type=section&id=Consolidated%20Income%20Statement) In Q1 2021, the company achieved total operating revenue of **1.995 billion Yuan**, up **181.26%** year-on-year, and net profit attributable to parent company shareholders of **254 million Yuan**, up **195.85%**, significantly enhancing profitability Key Items from Consolidated Income Statement (Q1 2021) | Item | Amount (Yuan) | Year-on-Year Change | | :--- | :--- | :--- | | Total Operating Revenue | 1,994,536,800.50 | +181.26% | | Total Operating Cost | 1,643,851,870.78 | +173.38% | | Operating Profit | 363,940,889.03 | +248.11% | | Total Profit | 364,628,010.00 | +251.47% | | Net Profit | 310,321,094.38 | +258.54% | | Net Profit Attributable to Parent Company Shareholders | 254,172,328.25 | +195.85% | [Parent Company Income Statement](index=16&type=section&id=Parent%20Company%20Income%20Statement) In Q1 2021, the parent company achieved operating revenue of **1.125 billion Yuan**, up **160.79%** year-on-year, and net profit of **50.66 million Yuan**, a **50.05% year-on-year decrease** Key Items from Parent Company Income Statement (Q1 2021) | Item | Amount (Yuan) | Year-on-Year Change | | :--- | :--- | :--- | | Operating Revenue | 1,125,254,949.67 | +160.79% | | Operating Profit | 60,170,929.05 | -49.08% | | Total Profit | 60,991,666.93 | -48.08% | | Net Profit | 50,663,402.91 | -50.05% | [Consolidated Cash Flow Statement](index=17&type=section&id=Consolidated%20Cash%20Flow%20Statement) In Q1 2021, net cash flow from operating activities was **230 million Yuan**, up **16.42%** year-on-year, while net cash flow from investing activities turned positive to **215 million Yuan** from **-256 million Yuan** due to wealth management product redemptions, and net cash outflow from financing activities was **231 million Yuan** for debt repayment and share repurchases Key Items from Consolidated Cash Flow Statement (Q1 2021) | Item | Amount (Yuan) | Last Year Same Period (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 229,569,623.19 | 197,190,457.14 | | Net Cash Flow from Investing Activities | 215,158,415.67 | -255,684,540.55 | | Net Cash Flow from Financing Activities | -231,357,023.08 | 106,802,902.84 | | Net Increase in Cash and Cash Equivalents | 214,305,361.38 | 34,328,432.93 | [Parent Company Cash Flow Statement](index=19&type=section&id=Parent%20Company%20Cash%20Flow%20Statement) In Q1 2021, the parent company's net cash flow from operating activities significantly increased to **362 million Yuan** from **47.08 million Yuan** in the prior year, with net cash flow from investing activities turning positive, and net cash outflow from financing activities at **231 million Yuan** Key Items from Parent Company Cash Flow Statement (Q1 2021) | Item | Amount (Yuan) | Last Year Same Period (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 361,754,948.26 | 47,084,029.09 | | Net Cash Flow from Investing Activities | 324,342,635.98 | -246,306,352.10 | | Net Cash Flow from Financing Activities | -231,379,353.81 | 106,802,902.84 | | Net Increase in Cash and Cash Equivalents | 442,061,249.87 | -109,241,990.17 | [4.2 Information on Adjustments to Financial Statements at the Beginning of the First Year of Adoption of New Lease Standards from 2021](index=21&type=section&id=4.2%20Information%20on%20Adjustments%20to%20Financial%20Statements%20at%20the%20Beginning%20of%20the%20First%20Year%20of%20Adoption%20of%20New%20Lease%20Standards%20from%202021) The company adopted new lease standards from January 1, 2021, retrospectively adjusting opening financial statements to recognize **76.78 million Yuan** in right-of-use assets and **62.66 million Yuan** in lease liabilities on the consolidated balance sheet, while reducing prepayments by **14.12 million Yuan**, using a simplified approach without restating comparative periods - The company began implementing the revised 'Accounting Standard for Business Enterprises No 21 – Leases' issued by the Ministry of Finance on January 1, 2021[79](index=79&type=chunk) - Under the new standards, the company applies the same accounting treatment to all leases (except short-term and low-value leases), recognizing right-of-use assets and lease liabilities[79](index=79&type=chunk) Major Impact of New Lease Standards Adoption on Opening Consolidated Financial Statements | Item | Before Adjustment (Yuan) | Adjustment Amount (Yuan) | After Adjustment (Yuan) | | :--- | :--- | :--- | :--- | | Prepayments | 140,822,929.78 | -14,122,198.59 | 126,700,731.19 | | Right-of-Use Assets | 0 | +76,783,070.98 | 76,783,070.98 | | Lease Liabilities | 0 | +62,660,872.39 | 62,660,872.39 | [4.4 Audit Report](index=26&type=section&id=4.4%20Audit%20Report) This quarterly report is unaudited - This quarterly financial report is unaudited[87](index=87&type=chunk)

Financial Performance - Total assets increased to ¥6,357,397,507.64, up 138.17% from the previous year[18] - Net assets attributable to shareholders reached ¥3,564,436,804.63, reflecting a 162.33% increase year-over-year[18] - Operating revenue for the first three quarters was ¥8,116,660,488.11, a 531.52% increase compared to the same period last year[18] - Net profit attributable to shareholders was ¥2,097,753,320.69, representing a 2,105.56% increase year-over-year[18] - Cash flow from operating activities amounted to ¥2,673,731,914.25, a significant increase of 2,601.70% compared to the previous year[18] - Basic earnings per share increased to ¥10.53, up 2,048.98% from the previous year[18] - The weighted average return on equity rose to 85.93%, an increase of 77.70 percentage points compared to the previous year[18] - Total revenue for the period reached ¥8,116,660,488.11, a significant increase of 531.52% compared to ¥1,285,262,447.59 in the same period last year[31] - The company reported a net profit attributable to minority shareholders of ¥312,217,850.18, a substantial increase of 3387.62% compared to ¥8,952,168.26 in the same period last year[32] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 2,077,402,698.86 RMB, representing a growth of 3,072.74% year-on-year[44] Sales and Market Performance - Sales of epidemic prevention protective products reached ¥6,107,694,520, a staggering increase of 11,599.15% year-over-year[21] - Domestic sales totaled ¥2,011,000,000, up 370.03% from the previous year, with epidemic prevention products contributing ¥1,461,000,000[21] - International sales were ¥6,098,000,000, a 612.14% increase year-over-year, with epidemic prevention products accounting for ¥4,646,000,000[21] - The company expects significant growth in net profit for the year 2020 compared to 2019, but there is uncertainty regarding the continued strong sales of pandemic-related protective products[44] Assets and Liabilities - The company's total liabilities decreased by 49.41% in bonds payable to ¥162,865,466.52 from ¥321,937,822.81, due to the conversion of some convertible bonds into shares[31] - Total liabilities as of September 30, 2020, were 2,426,256,281.71 RMB, up from 1,269,566,385.93 RMB at the end of 2019[55] - Total current liabilities were CNY 525,199,598.92, with short-term borrowings at CNY 292,487,185.54[98] Research and Development - The company is focusing on enhancing its research and development capabilities to drive innovation in new technologies[30] - Research and development expenses surged by 396.48% to ¥166,626,599.77 from ¥33,561,662.85, indicating a strong focus on innovation[31] - Research and development expenses in Q3 2020 amounted to ¥93,426,497.64, up from ¥11,017,612.97 in Q3 2019, reflecting an increase of approximately 747%[64] - The company reported a rise in research and development expenses due to increased investment in R&D during the reporting period[37] Strategic Initiatives - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[30] - There were no significant mergers or acquisitions reported during this period, indicating a focus on organic growth strategies[30] - The company aims to improve shareholder value through strategic initiatives and operational efficiencies in the upcoming quarters[30] - The company completed the acquisition of a 70% stake in Suzhou Medis Medical Sports Products Co., Ltd. for a total transaction amount of RMB 10.416 million[40] - The company has also invested RMB 30 million to acquire a 60% stake in Zhejiang Stanger Sports Protective Technology Co., Ltd. to enhance its product line in the sports rehabilitation sector[43] Cash Flow and Investments - The company reported cash inflows from investment activities totaling approximately ¥666.06 million, compared to ¥148.05 million in the previous year[81] - Cash outflows from investment activities amounted to approximately ¥1.94 billion, leading to a net cash flow from investment activities of approximately -¥1.27 billion[81] - Cash inflow from financing activities was approximately ¥1.05 billion, while cash outflows totaled approximately ¥1.07 billion, resulting in a net cash flow from financing activities of -¥27.65 million[82] - The company’s cash inflow from operating activities reflects a robust operational performance amidst challenging market conditions[86] Shareholder Information - The total number of shareholders at the end of the reporting period was 37,079, with the top ten shareholders holding a significant portion of the shares[26] - Zhejiang ZhenDe Holdings Co., Ltd. held 51.47% of the shares, making it the largest shareholder[28] - The second-largest shareholder, Shen Zhenfang, owned 4.39% of the shares, while the third-largest, Fang Shixiong, held 3.64%[28]

Financial Performance - The company's operating revenue for the first half of 2020 reached ¥3,819,840,910.57, a significant increase of 401.24% compared to ¥762,072,234.13 in the same period last year[25]. - Net profit attributable to shareholders was ¥988,568,649.97, representing a remarkable growth of 1,544.74% from ¥60,105,033.65 in the previous year[25]. - The net cash flow from operating activities was ¥2,276,369,995.53, up 8,419.07% from ¥26,720,862.58 in the same period last year[25]. - Basic earnings per share for the first half of 2020 were ¥5.04, a substantial increase of 1,525.81% from ¥0.31 in the same period last year[26]. - The diluted earnings per share were ¥4.45, reflecting an increase of 1,335.48% from ¥0.31 in the previous year[26]. - The weighted average return on net assets was 53.35%, an increase of 48.11 percentage points compared to 5.24% in the same period last year[26]. - The company achieved a main business revenue of 3,814.35 million yuan, a year-on-year increase of 404.78%[54]. - The net profit attributable to the parent company was 988.57 million yuan, a year-on-year increase of 1,544.74%[54]. - The company reported a total operating profit of ¥808,838,912.00 for the first half of 2020, compared to ¥35,374,621.69 in the same period of 2019, reflecting an increase of around 2,287%[197]. Assets and Liabilities - The company's total assets increased by 151.09% to ¥6,702,168,410.79 from ¥2,669,238,311.75 at the end of the previous year[25]. - The net assets attributable to shareholders rose by 70.07% to ¥2,310,904,221.78 compared to ¥1,358,786,069.59 at the end of the last year[25]. - Total liabilities reached ¥4,246,313,460.61, compared to ¥1,269,566,385.93 at the end of 2019, which is an increase of approximately 234.5%[181]. - Shareholders' equity rose to ¥2,455,854,950.18 from ¥1,399,671,925.82, representing an increase of about 75.5%[181]. - Cash and cash equivalents increased by 282.12% to ¥2,469,444,707.13 due to growth in sales and significant increases in advance payments and investment expenditures[45]. - Accounts receivable rose by 76.00% to ¥656,444,286.78, reflecting a substantial increase in sales revenue[45]. - Inventory increased by 142.60% to ¥1,045,460,023.87, attributed to heightened demand for protective products and corresponding increases in raw materials and finished goods[45]. Market and Sales Performance - The company's revenue for the reporting period increased significantly compared to the same period last year, primarily due to a surge in sales of pandemic-related protective products and the inclusion of Rocialle Healthcare Limited's 55% stake in the consolidated financial statements[27]. - Domestic sales amounted to 1,345.25 million yuan, a year-on-year increase of 413.26%[56]. - International sales reached 2,469.10 million yuan, a year-on-year increase of 400.28%[57]. - The company expanded its hospital coverage to over 4,900 hospitals, an increase of approximately 900 hospitals from the beginning of the reporting period[54]. - E-commerce sales grew to 114.07 million yuan, a year-on-year increase of 1,317.49%[57]. - The company is currently one of the top three exporters of medical dressings in China, benefiting from the country's position as the largest exporter in this segment globally[41]. Research and Development - Research and development expenses surged by 224.70% to ¥73,200,102.13 from ¥22,544,049.88, indicating a strong focus on innovation[64]. - The company holds 36 invention patents, enhancing its product line and market competitiveness through independent R&D efforts[49]. - The company is focusing on R&D innovation, with ongoing projects in modern wound dressings and new material applications for ostomy care[57]. Risks and Challenges - The report includes a detailed description of potential risks faced by the company, which is crucial for investor awareness[8]. - The company is currently facing uncertainty regarding the continued high sales of epidemic prevention products, which may affect future performance[89]. - The company faces risks related to product quality, industry policy changes, and market competition, particularly in the medical device sector, which is experiencing increased scrutiny and regulatory changes[93]. - The fluctuation in raw material costs, particularly for meltblown fabric and non-woven fabric, poses a risk to the company's operating performance[93]. Corporate Governance and Compliance - The company held its annual general meeting on May 22, 2020, where several key proposals were approved, including the financial report and the plan for related party transactions[96]. - The company has committed to fulfilling all pre-IPO promises and will disclose any failures to do so in a timely manner through designated media[110]. - The company has established a comprehensive quality management system to mitigate risks associated with product quality, but remains vulnerable to unforeseen factors such as disputes and regulatory penalties[93]. - The company has not engaged in any major related party transactions during the reporting period[122]. Investment and Acquisitions - The company completed the acquisition of a 70% stake in Suzhou Medis for CNY 104.16 million, with payments made totaling CNY 20.83 million during the reporting period[78]. - The company plans to invest 30 million yuan in cash to subscribe for 3.15 million yuan of registered capital in Zhejiang Stanger Sports Protective Equipment Technology Co., aiming to enhance its product line in the sports rehabilitation sector[94]. - The company has invested a total of ¥42,286.86 million in projects funded by its initial public offering, and ¥10,564.05 million in functional dressing and smart logistics center construction[62].

证券代码：603301 证券简称：振德医疗 公告编号：2019-068 振德医疗用品股份有限公司 关于参加浙江辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流工作，构建和谐投资者关系， 振德医疗用品股份有限公司（以下简称"公司"）将参加由中国证券 监督管理委员会浙江监管局指导、浙江上市公司协会与深圳市全景网 络有限公司联合举办的"沟通促发展 理性共成长"浙江辖区上市公 司投资者网上集体接待日活动，现将有关事项公告如下： 本次投资者集体接待日活动将通过深圳市全景网络有限公司提 供的网上平台举行，投资者可登录"全景·路演天下"网站 (http://rs.p5w.net）参与本次投资者集体接待日活动。网上交流互 动时间 2019 年 11 月 5 日（星期二）下午 15:30 至 17:00。届时公司 将通过网络在线交流形式与投资者就公司治理、发展战略、经营状况 等投资者关心的问题进行沟通。 欢迎广大投资者积极参与。 特此公告。 振德医疗用品股份有限公 ...

Financial Performance - Operating revenue for the first nine months increased by 8.57% to CNY 1,028,084,431.37 compared to the same period last year[6] - Net profit attributable to shareholders grew by 18.58% to CNY 85,255,943.31 year-on-year[6] - Total operating revenue for Q3 was ¥363,006,137.45, an increase of 8.1% from ¥335,917,620.44 in the same period last year[27] - Net profit for Q3 reached ¥33,147,352.54, representing a 29.2% increase compared to ¥25,629,920.45 in the previous year[29] - Year-to-date operating revenue reached ¥1,028,084,431.37, up 8.6% from ¥946,945,090.96 in the previous year[27] - Year-to-date net profit was ¥85,307,963.44, an increase of 18.4% from ¥71,942,622.88 year-over-year[29] Assets and Liabilities - Total assets increased by 45.41% to CNY 1,881,385,458.57 compared to the end of the previous year[6] - Total liabilities increased to CNY 801,799,301.90 from CNY 733,692,869.42, showing a growth of about 9.3%[21] - Current assets rose to CNY 1,107,210,593.40 from CNY 576,076,861.50, marking an increase of about 92.1%[20] - Cash and cash equivalents significantly increased to CNY 309,491,639.42 from CNY 114,391,821.80, a growth of approximately 170.5%[19] - Accounts receivable grew to CNY 250,713,994.88 from CNY 189,269,286.45, reflecting an increase of about 32.4%[19] - Inventory surged to CNY 325,190,243.59 from CNY 207,606,482.11, indicating a rise of approximately 56.5%[19] Shareholder Information - The total number of shareholders reached 18,717 at the end of the reporting period[10] - The largest shareholder, Zhejiang Zhend Medical Holdings Co., Ltd., holds 55.71% of the shares[10] - Basic and diluted earnings per share remained unchanged at CNY 0.96[7] Cash Flow - Net cash flow from operating activities decreased by 164.20% to -CNY 67,359,573.61 compared to the previous year[6] - Net cash flow from financing activities surged to ¥452,178,584.81, a 1,615.13% increase from ¥26,364,119.03, driven by funds raised from the public offering[13] - The net cash flow from operating activities was negative at CNY -67,359,573.61, compared to a positive CNY 104,928,686.38 in the previous year, reflecting a significant decline[37] - The total cash outflow from operating activities was 1,080,436,180.00 RMB, compared to 1,005,063,103.09 RMB in the previous year[38] Investments and Expenses - R&D expenses for Q3 amounted to ¥18,627,081.01, a significant increase of 73.2% from ¥10,770,938.53 in the same quarter last year[28] - The company plans to continue investing in R&D to drive future growth and innovation[28] - Long-term investments increased to CNY 440,626,349.44 from CNY 213,967,134.64, reflecting a growth of about 106.5%[24] Other Financial Metrics - The weighted average return on equity decreased by 5.08 percentage points to 10.11%[7] - The company reported non-recurring gains and losses totaling CNY 9,601,548.18 for the year-to-date[9] - The profit margin for Q3 was approximately 9.1%, compared to 7.6% in the same quarter last year[29]

Financial Performance - The company's operating revenue for the first half of 2018 was ¥665,078,293.92, representing an increase of 8.85% compared to ¥611,027,470.52 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥52,102,937.84, up 12.53% from ¥46,299,457.01 in the previous year[20]. - The net profit after deducting non-recurring gains and losses decreased by 24.62%, amounting to ¥28,617,210.76 compared to ¥37,964,575.94 in the same period last year[20]. - The net cash flow from operating activities was negative at -¥105,940,710.32, a decrease of 243.52% compared to ¥73,814,575.40 in the previous year[20]. - The gross profit margin for the reporting period was impacted by an increase in operating costs, with operating costs rising by 10.65% to CNY 476.12 million[43]. - The company's R&D expenditure was CNY 20.94 million, a 4.97% increase from the previous year, indicating a commitment to innovation[43]. - The total profit for the first half of 2018 was CNY 63,004,236.00, compared to CNY 55,537,191.57 in the previous year, marking an increase of 13.4%[115]. - The company's operating profit decreased to CNY 28,114,297.37 from CNY 37,448,449.70, a decline of 25.5% year-on-year[117]. Assets and Liabilities - Total assets rose by 38.62% to ¥1,793,523,471.49 from ¥1,293,887,706.71 at the end of the previous year[20]. - The company's total liabilities were RMB 684,504,580.72, slightly up from RMB 663,113,835.27, indicating a 3.1% increase[108]. - The company's accounts receivable increased by 31.04% to 248,013,484.75 RMB, attributed to sales growth during the reporting period[47]. - The company's inventory rose by 38.60% to 287,743,266.99 RMB, primarily due to raw material procurement for stockpiling[48]. - The total assets of the company reached RMB 1,793,523,471.49, compared to RMB 1,293,887,706.71 at the start of the period, marking a growth of 38.7%[108]. - The company's cash and cash equivalents increased to RMB 175,795,949.93 from RMB 114,391,821.80, a growth of 53.7%[107]. Shareholder Information - The company issued 25 million shares at a price of ¥19.82 per share, raising a total of ¥495.5 million, with a net amount of ¥434.28 million after expenses[22]. - The total share capital of the company increased from 75,000,000 shares to 100,000,000 shares after the issuance of 25,000,000 new shares[94]. - The largest shareholder, Zhejiang ZhenDe, holds 55,710,000 shares, representing 55.71% of the total shares[98]. - The top ten shareholders collectively hold 66.56% of the total shares, indicating a concentrated ownership structure[98]. - Major shareholders, including Shen Zhenfang and Xu Dasheng, are restricted from transferring their shares for 12 months after the listing date[73]. Market and Industry Position - The company has established a comprehensive marketing network covering major global markets, with products exported to multiple countries across six continents, maintaining a position among the top three medical dressing exporters in China[27]. - The global medical device market was valued at USD 387 billion in 2016 and is projected to grow at a compound annual growth rate (CAGR) of 5.1%, reaching USD 522 billion by 2022[32]. - The medical dressing industry in China is experiencing rapid growth due to increased healthcare consumption and supportive government policies, presenting significant development opportunities[33]. - The company is actively expanding into new product areas such as cleaning and disinfection, ostomy care, and sports rehabilitation, aiming to provide comprehensive solutions for wound care and infection control[27]. Corporate Governance and Compliance - The company held one annual general meeting and three extraordinary general meetings during the reporting period[69]. - The company has committed to fulfilling its obligations as per the promises made by its actual controllers and shareholders during the reporting period[72]. - The company will publicly disclose reasons for any non-compliance with commitments in the shareholders' meeting and relevant publications[73]. - The company appointed Tianjian Accounting Firm as the auditor for the 2018 fiscal year, approved at the 2017 annual shareholders' meeting[77]. - There were no significant lawsuits or arbitration matters during the reporting period[77]. Environmental and Social Responsibility - The company’s subsidiary, Xuchang Zhend, is classified as a key wastewater pollutant unit and has reported actual emissions of chemical oxygen demand at 52.58 mg/L, which is below the standard limit of 150 mg/L[81]. - The company has implemented an emergency response plan for environmental incidents and conducts annual drills to ensure effective handling of such events[85]. - The company has not experienced any environmental violations or penalties during the reporting period[88]. Accounting and Financial Reporting - The company has not made any changes to accounting policies or estimates compared to the previous accounting period[90]. - The company adheres to the accounting standards, ensuring that financial statements accurately reflect its financial position, operating results, and cash flows[140]. - The company recognizes foreign currency transactions at the exchange rate on the transaction date, with differences accounted for in the current period's profit or loss[147]. - Revenue from sales is recognized when the risks and rewards of ownership are transferred to the buyer, and the amount can be reliably measured[183].

2018 年第一季度报告 公司代码：603301 公司简称：振德医疗 振德医疗用品股份有限公司 2018 年第一季度报告 1 / 17 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 6 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | | --- | --- | --- | --- | --- | --- | | | | | 减(%) | | | | 总资产 | 1,367,657,597.00 | 1,293,887,706.71 | | | 5.70 | | 归属于上市公司 | 578,947,501.22 | 559,234,367.84 | | | 3.53 | | 股东的净资产 | | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | | 经营活动产生的 | -14,096,097.60 | 22,565,097 ...